Results 61 to 70 of about 8,366 (155)

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam

Journal of Family Medicine and Primary Care
ABSTRACT Background: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem resistant Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics.
Sunali, Mithilesh Kumar Jha, Mukesh Kumar, Maneesh Kumar, Nishant Ranjan   +4 more
openaire   +3 more sources

Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance

mSystems
Klebsiella pneumoniae carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive.
Jie Wei, Jinyu Huang, Chunhong Zou, Shimei Shen, Barry N. Kreiswirth, Ailong Huang, Shifeng Huang, Liang Chen, Deqiang Wang, Siqiang Niu   +9 more
doaj   +1 more source

The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020

Eurosurveillance
Background Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens.
Berit Muller-Pebody
doaj   +1 more source

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies

Diagnostic Microbiology and Infectious Disease
We described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω-loop.
Amadesi S., Amedeo A., Rinaldi M., Palombo M., Giannella M., Gaibani P.   +5 more
openaire   +2 more sources

Ceftazidime/avibactam for specified infections [PDF]

Australian Prescriber, 2020
openaire   +2 more sources

Effectiveness of Ceftazidime/Avibactam treatment for infections caused by Klebsiella pneumoniae Carbapenemase (KPC), a 30-day mortality perspective. Comparison of results with control groups treated with other antibiotics

Journal of Education, Health and Sport
Introduction: Infections caused by Klebsiella pneumoniae carbapenemase (KPC) pose a significant clinical challenge due to increasing antibiotic resistance.
Patrycja Paschke, Igor Miczek, Maria Sambura, Sara Rosołowska-Żak, Julia Pałuchowska, Anna Szymkowicz   +5 more
doaj   +1 more source

Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia

Journal of Infection and Public Health
Background: Ceftazidime-avibactam (CZA) is the preferred treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). This study aimed to investigate the prognostic factors of 28-day mortality and 14-day clinical failure in patients treated with CZA for CZA-susceptible CRKP bacteremia.
Yi-Tsung Lin, Shih-Neng Lin, Chien Chuang, Szu-Yu Liu, Yu-Chien Ho, Chih-Han Juan, Hsiang-Ling Ho, Sheng-Hua Chou   +7 more
openaire   +2 more sources

Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration

Pharmacology Research & Perspectives
Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in ...
Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher‐Bournaud, Jean‐Marc Tréluyer, Mehdi Oualha   +5 more
doaj   +1 more source

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185

mBio
β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an Escherichia coli clinical strain isolated from a patient who underwent ...
Akito Kawai, William C. Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L. Aitken, William C. Bachman, Christi L. McElheny, Micah M. Bhatti, Ryan K. Shields, Samuel A. Shelburne, Yohei Doi   +10 more
doaj   +1 more source

Will Ceftazidime-Avibactam Replace Polymyxins in Asia?

Clinical Infectious Diseases, 2021
Sock Hoon, Tan, Narendran, Koomanan, Shimin Jasmine, Chung, Andrea Lay-Hoon, Kwa   +3 more
openaire   +2 more sources